Health stopped being a sacrifice aesthetic and became a status aesthetic. Protein, gut health and "no added sugar" are now how mainstream consumers shop the treat aisle, and GLP-1 adoption (~1 in 8 US adults) is compressing appetite while raising the bar for what a snack must justify. Indulgence occasions aren't disappearing; they're being re-priced and re-formulated.
PepsiCo paid $1.95B for Poppi (2025). OLIPOP reached a $1.85B valuation, profitably. Hershey paid ~$750M for LesserEvil; PepsiCo $1.2B for Siete. David hit ~$100M year-one revenue at a $725M valuation, then raised at $2.25B in September 2026. Strategics have stalled innovation engines and are paying 3–4x revenue for brands that own a need-state.
Incumbents can't make these products without indicting their core portfolio, and their brands carry zero permission in health. Startups win on founder taste, formulation speed, and audiences they bring with them (Feastables: $0→$250M in <3 yrs on creator distribution).
AU runs the US playbook with a 2–3 year lag, a chemist-channel beachhead US brands don't have (Chemist Warehouse), the world's most consolidated grocery duopoly (brutal, but national in one deal), and structural kids'-snack demand via school canteen policy. Remedy (~A$163M rev) and Noshu (A$4M→A$38M in 4 yrs) prove local scale; FUNDAY proves exportability; NOON went from national Woolworths (Jan 2026) to about 2,000 US Target stores (Aug 2026).
Taste parity is the entry ticket, not the win. The win is repeat purchase (habit formats beat novelty), supply-chain ownership (David bought its ingredient supplier; LesserEvil self-manufactures), and distribution as moat: a creator audience, a pharmacy chain, or a school canteen list.
US healthy soda is post-peak for new entrants. Gummies are crowded. Claims risk is real (Poppi settled a prebiotic class action pre-exit). And the best operators (Chomps, ~$900M rev, near-bootstrapped) sometimes don't need venture money at all. Founder selection is the whole game.